
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024
Description
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024
DelveInsight’s, “Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024” report provides comprehensive insights about 5+ companies and 8+ pipeline drugs in Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
Muscarinic acetylcholine receptor M1 (M1 mAChR) antagonists are a class of drugs that block the action of acetylcholine at the M1 subtype of muscarinic receptors. These receptors are part of the G-protein coupled receptor family and are predominantly found in the central nervous system, particularly in areas involved in cognitive function such as the cerebral cortex and hippocampus. M1 receptors play a critical role in modulating neurotransmission, influencing processes such as memory, learning, and attention.
Muscarinic acetylcholine receptor M1 antagonists typically contain several structural features essential for their activity. These include aromatic rings, which are crucial for binding to the receptor, and tertiary amines, which contribute to the molecule's basicity and ability to form ionic interactions with the receptor. They also often have linkages, such as ester or ether bonds, connecting different parts of the molecule, influencing pharmacokinetics and binding properties. Some M1 antagonists feature bicyclic or tricyclic ring systems, enhancing their ability to fit into the receptor's binding site. Examples include pirenzepine, dicyclomine, and biperiden, each showcasing variations of these common structural elements.
M1 mAChR antagonists work by binding to the M1 receptor and preventing acetylcholine from activating it. This blockade can alter neurotransmitter release and neuronal excitability, leading to various physiological and behavioral effects. Since M1 receptors are implicated in cognitive processes, their antagonists can impact memory and learning. However, the exact outcomes depend on the specific antagonist and the context in which it is used. M1 mAChR antagonists have potential therapeutic applications, including treating neurological disorders like Alzheimer's disease, serving as adjunct therapy in schizophrenia, and managing gastrointestinal conditions such as peptic ulcers and irritable bowel syndrome. However, their use is limited due to the broad distribution of muscarinic receptors and potential side effects.
Examples of M1 mAChR Antagonists Some known M1 antagonists include
- Pirenzepine: Primarily used in the treatment of peptic ulcers due to its ability to reduce gastric acid secretion.
- Dicyclomine: Used to treat irritable bowel syndrome by reducing muscle spasms in the gastrointestinal tract.
- Biperiden: Sometimes used in the treatment of Parkinson's disease and drug-induced extrapyramidal symptoms.
""Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscarinic Acetylcholine Receptor M1 Antagonists pipeline landscape is provided which includes the disease overview and Muscarinic Acetylcholine Receptor M1 Antagonists treatment guidelines. The assessment part of the report embraces, in depth Muscarinic Acetylcholine Receptor M1 Antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscarinic Acetylcholine Receptor M1 Antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Muscarinic Acetylcholine Receptor M1 Antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Muscarinic Acetylcholine Receptor M1 Antagonists.
This segment of the Muscarinic Acetylcholine Receptor M1 Antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Muscarinic Acetylcholine Receptor M1 Antagonists Emerging Drugs
- TNX-102 SL: Tonix Pharmaceuticals
Further product details are provided in the report……..
Muscarinic Acetylcholine Receptor M1 Antagonists: Therapeutic Assessment
This segment of the report provides insights about the different Muscarinic Acetylcholine Receptor M1 Antagonists drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Muscarinic Acetylcholine Receptor M1 Antagonists
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Muscarinic Acetylcholine Receptor M1 Antagonists: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscarinic Acetylcholine Receptor M1 Antagonists therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscarinic Acetylcholine Receptor M1 Antagonists drugs.
Muscarinic Acetylcholine Receptor M1 Antagonists Report Insights
- Muscarinic Acetylcholine Receptor M1 Antagonists Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Muscarinic Acetylcholine Receptor M1 Antagonists drugs?
- How many Muscarinic Acetylcholine Receptor M1 Antagonists drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscarinic Acetylcholine Receptor M1 Antagonists?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscarinic Acetylcholine Receptor M1 Antagonists therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Muscarinic Acetylcholine Receptor M1 Antagonists and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tonix Pharmaceuticals
- Bristol Myers Squibb
- WinSanTor, Inc
- Apnimed
- TNX-102 SL
- KarXT
- WST-057
- Aroxybutynin/atomoxetine
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Muscarinic Acetylcholine Receptor M1 Antagonists: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Muscarinic Acetylcholine Receptor M1 Antagonists– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- TNX-102 SL: Tonix Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
- Muscarinic Acetylcholine Receptor M1 Antagonists Key Products
- Muscarinic Acetylcholine Receptor M1 Antagonists- Unmet Needs
- Muscarinic Acetylcholine Receptor M1 Antagonists- Market Drivers and Barriers
- Muscarinic Acetylcholine Receptor M1 Antagonists- Future Perspectives and Conclusion
- Muscarinic Acetylcholine Receptor M1 Antagonists Analyst Views
- Muscarinic Acetylcholine Receptor M1 Antagonists Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.